2026 Arlene H. Sharpe: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Best Female Scientists	165	77	69	44	40	530	124771
Best Scientists	165	1029	945	609	548	530	124771
Immunology	169	57	54	40	38	521	132866
Medicine	169	534	485	314	281	528	132925

Research.com Recognitions

2026 - Research.com Immunology in United States Leader Award
2025 - Research.com Best Female Scientists Award
2025 - Research.com Immunology in United States Leader Award
2020 - Fellow, National Academy of Inventors
2018 - Member of the National Academy of Medicine (NAM)
2018 - Member of the National Academy of Sciences
2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.
2006 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Arlene H. Sharpe is affiliated with Harvard University in the United States and has contributed extensively to the fields of medicine and immunology. Their research primarily focuses on immunology, oncology, molecular biology, genetics, and cancer research, with a significant emphasis on cancer immunotherapy and immune cell function. The body of work includes investigations into cancer immunotherapy and biomarkers, immune cell function and interaction, CAR-T cell therapy research, T-cell and B-cell immunology, immune cells in cancer, immunotherapy and immune responses, and glioma diagnosis and treatment.

Their recent publications include:

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020, Nature Medicine)
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity (2020, Cell)
Spatially organized multicellular immune hubs in human colorectal cancer (2021, Cell)
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma (2021, Cancer Cell)
The aging lung: Physiology, disease, and immunity (2021, Cell)

Frequent co-authors in their work include:

Gordon J. Freeman
Martin W. LaFleur
Kelly P. Burke
Marcia C. Haigis
Kristen E. Pauken

Sharpe's work has been published in a variety of scientific journals, with a notable presence in:

Cancer Immunology Research
The Journal of Immunology
bioRxiv (Cold Spring Harbor Laboratory)
Cancer Research
The Journal of Experimental Medicine

They have received recognition from several scientific organizations, including election to the National Academy of Sciences and the National Academy of Medicine in 2018. Additional honors include being named a Fellow of the National Academy of Inventors in 2020 and a Fellow of the American Association for the Advancement of Science in 2006. In 2017, Sharpe was awarded the Warren Alpert Foundation Prize for contributions related to the development of immune checkpoint blockade as a cancer therapy.

Best Publications

PD-1 and its ligands in tolerance and immunity

Mary E. Keir;Manish J. Butte;Gordon J. Freeman;Arlene H. Sharpe

6316
Citations
Restoring function in exhausted CD8 T cells during chronic viral infection.

Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu

4964
Citations
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

E A Tivol;F Borriello;A N Schweitzer;W P Lynch

3791
Citations
PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary

3680
Citations
THE B7 FAMILY REVISITED

Rebecca J. Greenwald;Gordon J. Freeman;Arlene H. Sharpe

3152
Citations
The PD-1 pathway in tolerance and autoimmunity

Loise M. Francisco;Peter T. Sage;Arlene H. Sharpe;Arlene H. Sharpe

2947
Citations
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development

Annie Yang;Ronen Schweitzer;Deqin Sun;Mourad Kaghad

2774
Citations
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

Benoît Salomon;Deborah J Lenschow;Lesley Rhee;Neda Ashourian

2589
Citations
The B7–CD28 superfamily

Arlene H Sharpe;Gordon J Freeman

2464
Citations
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Loise Marie Francisco;Victor H. Salinas;Keturah Elise Brown;Vijay K. Vanguri;Vijay K. Vanguri

2384
Citations
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Matthew M. Gubin;Xiuli Zhang;Heiko Schuster;Etienne Caron

2186
Citations
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

Manish J. Butte;Mary E. Keir;Theresa B. Phamduy;Arlene H. Sharpe

2120
Citations
Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy

Se Jin Im;Masao Hashimoto;Michael Y Gerner;Michael Y Gerner;Junghwa Lee

2060
Citations
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.

Brian C. Miller;Debattama R. Sen;Debattama R. Sen;Rose Al Abosy;Rose Al Abosy;Kevin Bi;Kevin Bi

1949
Citations
The diverse functions of the PD1 inhibitory pathway.

Arlene H Sharpe;Kristen E Pauken

1906
Citations
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

Arlene H Sharpe;E John Wherry;Rafi Ahmed;Gordon J Freeman

1861
Citations
Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.

Qing Wang;Terryl Stacy;Michael Binder;Miguel Marin-Padilla

1765
Citations
Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice

Lori D. Klaman;Olivier Boss;Odile D. Peroni;Jason K. Kim

1568
Citations
Defining ‘T cell exhaustion’

Christian U Blank;W Nicholas Haining;Werner Held;Patrick G Hogan;Patrick G Hogan

1487
Citations
Tissue expression of PD-L1 mediates peripheral T cell tolerance

Mary E. Keir;Spencer C. Liang;Indira Guleria;Yvette E. Latchman

1446
Citations
The Ikaros gene is required for the development of all lymphoid lineages.

Katia Georgopoulos;Michael Bigby;Jin-Hong Wang;Arpad Molnar

1393
Citations

Frequent Co-Authors

Gordon J. Freeman Harvard University

W. Nicholas Haining Arsenal Biosciences (United States)

Vijay K. Kuchroo Harvard University

Rafi Ahmed Emory University

Bruce R. Blazar University of Minnesota

E. John Wherry University of Pennsylvania

Mohamed H. Sayegh American University of Beirut

Bernard N. Fields Harvard University

Hideo Yagita Juntendo University

Marcia C. Haigis Harvard University

External Links

Personal website of Arlene H. Sharpe

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields can broaden career opportunities. Many students consider pursuing a nursing path, such as becoming a Nurse Practitioner. Some programs are known for being the easiest nurse practitioner program, offering a more accessible route for busy professionals.

Mental health is a crucial aspect connected to immunological disorders, prompting interest in Psychiatric Mental Health Nurse Practitioner (PMHNP) programs. When selecting a program, it’s important to look for options with strong clinical training. The pmhnp programs online with best clinical placement ensure hands-on experience, vital for career success.

Cost is also a significant factor for many students. Discovering affordable pmhnp programs can make advanced nursing education more attainable without sacrificing quality. This is particularly beneficial for those balancing work and study.

Advanced degrees, such as the Doctorate in Nursing Practice (DNP), often lead to higher earning potential. Understanding the doctorate in nursing salary can help candidates evaluate the return on investment for these programs across different states.